title: Recent advances in protection against doxorubicin-induced toxicity.
abstract: Anthracycline antibiotics are among the most effective and commonly used anticancer drugs. Unfortunately, their clinical use is restricted by dose-dependent toxicity. Doxorubicin is an anthracycline antibiotic and cytotoxic (antineoplastic) agent. It is commonly used against ovarian, breast, lung, uterine and cervical cancers, Hodgkin's disease, soft tissue and primary bone sarcomas, as well against in several other cancer types. It has been shown that free radicals are involved in doxorubicin-induced toxicity. Doxorubicin causes the generation of free radicals and the induction of oxidative stress, associated with cellular injury. This review illustrates recent applications of different natural products, drugs, drug delivery systems, and approaches for protection against doxorubicin-induced toxicity (2006-present).
authors.affiliation: University of Ljubljana, Askerceva 7, 1000 Ljubljana, Slovenia. injacrade@gmail.com
authors.forename: R
authors.initials: R
authors.lastname: Injac
authors.forename: B
authors.initials: B
authors.lastname: Strukelj
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D000975:Antioxidants / Q000627:therapeutic use; D004317:Doxorubicin / Q000633:toxicity*; D016503:Drug Delivery Systems; D005609:Free Radicals; D006801:Humans; D008081:Liposomes / Q000737:chemistry; D053758:Nanoparticles / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy*; D018384:Oxidative Stress
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D000975:Antioxidants; D005609:Free Radicals; D008081:Liposomes; D004317:Doxorubicin